Therapeutics

$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Traders Ought to Contact Block & Leviton to Probably Get better Losses
Company Announcement

$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Traders Ought to Contact Block & Leviton to Probably Get better Losses

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Section 2/3 Scientific Trial of SIL204 in Domestically Superior Pancreatic Most cancers
Stock Market

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Section 2/3 Scientific Trial of SIL204 in Domestically Superior Pancreatic Most cancers

Vivoryon Therapeutics N.V. Gives Replace on Rising Physique of Proof Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Company Announcement

Vivoryon Therapeutics N.V. Gives Replace on Rising Physique of Proof Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Pruritus Therapeutics Market Measurement is Projected to Attain USD 15.58 Billion by 2035 Because of the Growing Instances of Persistent Inflammatory Pores and skin Ailments Globally | SNS Insider
Press Releases

Pruritus Therapeutics Market Measurement is Projected to Attain USD 15.58 Billion by 2035 Because of the Growing Instances of Persistent Inflammatory Pores and skin Ailments Globally | SNS Insider

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Part 2/3 Scientific Trial of SIL204 in Regionally Superior Pancreatic Most cancers
Stock Market

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Part 2/3 Scientific Trial of SIL204 in Regionally Superior Pancreatic Most cancers

Galimedix Therapeutics presents sturdy pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Press Releases

Galimedix Therapeutics presents sturdy pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Mineralys Therapeutics Studies Inducement Awards Below Nasdaq Itemizing Rule 5635(c)(4)
Stock Market

Mineralys Therapeutics Studies Inducement Awards Below Nasdaq Itemizing Rule 5635(c)(4)